Abstract:Evidence indicates that schizophrenia and in particular negative symptoms and deficit schizophrenia are accompanied by neurocognitive impairments and changes in the patterning of the tryptophan catabolite (TRYCAT) pathway. This cross-sectional study was carried out to examine the associations between cognitive functions (as measured with Consortium to Establish a Registry for Alzheimer’s disease (CERAD)) and TRYCAT pathway patterning in patients with (n = 40) and without (n = 40) deficit schizophrenia and normal controls (n = 40). Cognitive measures were assessed with the Verbal Fluency Test (VFT), Boston Naming Test (BNT), Mini-Mental State Examination (MMSE), Word List Memory (WLM), Constructional Praxis, Word List Recall (WLRecall), and Word List Recognition (WLRecognition), while TRYCAT measurements assessed the IgA/IgM responses to noxious TRYCATs, namely quinolinic acid (QA), 3-OH-kynurenine (3HK), picolinic acid (PA), and xanthurenic (XA) acid, and more protective (PRO) TRYCATs, including kynurenic acid (KA) and anthranilic acid (AA). IgA NOX/PRO, IgM KA/3HK, and IgA/IgM NOX/PRO ratios were computed. Schizophrenia was accompanied by lower VFT and WLM, while BNT (dysnomia) and MMSE are significantly lower in multiple- than first-episode schizophrenia. Deficit schizophrenia is strongly associated with worse outcomes on VFT, MMSE, WLM, WLRecall, WLRecognition, and delayed recall savings and increased false memories. Around 40–50% of the variance in negative symptoms’ scores was explained by VFT, WLM, WLRecall, and MMSE. Increases in IgA NOX/PRO, IgM KA/3HK, and/or IgA/IgM NOX/PRO ratios were associated with impairments in VFT, BNT, MMSE, WLM, WLRecall, WLRecognition, and false-memory creation. In conclusion, nondeficit schizophrenia is accompanied by mild memory impairments, while disease progression is accompanied by broader cognitive impairments. Deficit schizophrenia and negative symptoms are strongly associated with deficits in working memory, delayed recall and recognition, and increased false-memory creation. These cognitive impairments and memory deficits are in part explained by increased production and/or attenuated regulation of TRYCATs with neurotoxic, excitotoxic, immune-inflammatory, oxidative, and nitrosative potential, which may contribute to neuroprogression.

Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning

Differences in Inflammatory Marker Profiles and Cognitive Functioning Between Deficit and Nondeficit Schizophrenia

Deficit Schizophrenia is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (trycats): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation

Towards a New Classification of Stable Phase Schizophrenia into Major and Simple Neuro-Cognitive Psychosis: Results of Unsupervised Machine Learning Analysis

Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia

Pattern recognition memory in deficit and nondeficit schizophrenia patients.

Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables

A Neuromarker for Deficit Syndrome in Schizophrenia from a Combination of Structural and Functional Magnetic Resonance Imaging

Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid

In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome

Specific Neuropsychological Deficits in Schizophrenic Patients with Preserved Intellectual Function

Spatial working memory in patients with deficit and nondeficit schizophrenia

In (deficit) Schizophrenia, a General Cognitive Decline Partly Mediates the Effects of Neuro-Immune and Neuro-Oxidative Toxicity on the Symptomatome and Quality of Life

The novel schizophrenia subgroup "major neurocognitive psychosis" is validated as a distinct class through the analysis of immune-linked neurotoxicity biomarkers and neurocognitive deficits

Convergence and Divergence of Neurocognitive Patterns in Schizophrenia and Depression.

The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia Are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.

Deficits in Generalized Cognitive Ability, Visual Sensorimotor Function, and Inhibitory Control Represent Discrete Domains of Neurobehavioral Deficit in Psychotic Disorders.

In Schizophrenia, Low Natural IgM Antibody Titers to Oxidative Specific Epitopes and Higher IgM Responses to Nitrated and Nitrosylated Proteins Strongly Predict Negative Symptoms, Neurocognitive Impairments and the Deficit Syndrome

Episodic Memory and Delayed Recall Are Significantly More Impaired in Younger Patients with Deficit Schizophrenia Than in Elderly Patients with Amnestic Mild Cognitive Impairment

The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study

In Schizophrenia, Increased Plasma Igm/Iga Responses to Gut Commensal Bacteria Are Associated with Negative Symptoms, Neurocognitive Impairments and the Deficit Phenotype